Drug-coated balloons in interventional cardiology

Francesco Giannini, Charbel Naim, Charis Costopoulos, Azeem Latib, Antonio Colombo

Research output: Contribution to journalArticlepeer-review

Abstract

Over the last few years, drug-coated balloon (DCB) therapy has emerged as a promising therapeutic intervention for the management of obstructive cardiovascular disease. The dictum of this novel technology is that effective prevention of restenosis can be achieved by the short-term transfer of antiproliferative drug to local arterial tissue by means of a single prolonged balloon angioplasty dilatation. Its main attraction is that no foreign body is implanted eliminating thus the risk of late inflammatory response to device components without preventing positive remodeling. Here, we discuss the evidence regarding the effectiveness of DCB in different lesion types and clinical settings as well as the types of DCB commercially available or under development.

Original languageEnglish
Pages (from-to)1379-1391
Number of pages13
JournalExpert Review of Cardiovascular Therapy
Volume11
Issue number10
DOIs
Publication statusPublished - 2013

Keywords

  • Bailout stenting
  • Bifurcation lesion
  • Coronary artery disease
  • De novo coronary lesion
  • Diffuse coronary disease
  • Drug carrier
  • Drug-coated balloon
  • Excipient
  • in-stent restenosis
  • Paclitaxel
  • Percutaneous coronary intervention
  • Semicompliant balloons
  • Small vessel disease

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Internal Medicine

Fingerprint Dive into the research topics of 'Drug-coated balloons in interventional cardiology'. Together they form a unique fingerprint.

Cite this